Who
John B. Bode
Director
Company insider
Files Form 4 as: Director, SPAR Group; Director, Zevra Therapeutics; Director, Newton Golf Company; Director, Fision; EVP and CFO, Tribune Publishing Co.
In numbers
- Trades disclosed
- 39
- Buys
- 6
- Sells
- 0
- Bought
- $337K
- Sold
- $0
- Companies
- 5
- Companies where not an officer
- 4
- First trade
- 29 Aug 2014
- Last trade
- 29 Sep 2026
- Last filed
- 1 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 29 Sep 2026filed 1 Oct 2026 | SPAR GroupBusiness Services | SEC FORM 4 Code A | —110,000 | filing |
| 24 Mar 2026filed 26 Mar 2026 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Code M | $195K39,200 at $4.97 | filing |
| 24 Mar 2026filed 26 Mar 2026 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Code M | $192K39,200 at $4.89 | filing |
| 24 Mar 2026filed 26 Mar 2026 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —39,200 at $0.00 | filing |
| 24 Mar 2026filed 26 Mar 2026 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —39,200 at $0.00 | filing |
| 24 Mar 2026filed 26 Mar 2026 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —39,200 at $0.00 | filing |
| 24 Mar 2026filed 26 Mar 2026 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —39,200 at $0.00 | filing |
| 24 Mar 2026filed 26 Mar 2026 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Code M | $195K39,200 at $4.97 | filing |
| 24 Mar 2026filed 26 Mar 2026 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Code M | $192K39,200 at $4.89 | filing |
| 30 Jan 2026filed 3 Feb 2026 | NWTG Newton Golf CompanyLeisure Products & Vehicles | SEC FORM 4 Code A | —18,549 at $0.00 | filing |
| 30 Jan 2026filed 3 Feb 2026 | NWTG Newton Golf CompanyLeisure Products & Vehicles | SEC FORM 4 Code A | —18,549 at $0.00 | filing |
| 19 Aug 2025filed 20 Aug 2025 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Bought | $46K5,000 at $9.17 | filing |
| 29 May 2025filed 30 May 2025 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 19 Mar 2025filed 21 Mar 2025 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Bought | $80K10,000 at $7.96 | filing |
| 12 Jul 2024filed 15 Jul 2024 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Bought | $59K10,000 at $5.87 | filing |
| 13 May 2024filed 15 May 2024 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,200 at $0.00 | filing |
| 5 Sep 2023filed 6 Sep 2023 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Bought | $51K10,000 at $5.13 | filing |
| 18 May 2023filed 19 May 2023 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Bought | $7,0061,390 at $5.04 | filing |
| 18 May 2023filed 19 May 2023 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Bought | $1,512300 at $5.04 | filing |
| 18 May 2023filed 19 May 2023 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Bought | $5,0401,000 at $5.04 | filing |
News
No headline names them, or the companies they trade most, lately.